Richard Carroll, Ph.D.
Associate Professor of Pharmaceutical Sciences
Dr. Carroll joined the Department of Pharmaceutical Sciences in October, 2007. He received his Bachelor of Science (Biology), Master of Science (Chemistry), and Ph.D. (Chemistry) from the University of Toledo in Toledo, Ohio. In 1991, he joined the Neuroscience Therapeutics Department at Parke-Davis in Ann Arbor, MI, USA. During his tenure at Parke-Davis, Dr. Carroll was involved in the discovery of novel compounds aimed at treating neurodegenerative diseases.
After Parke-Davis merged with Pfizer in 1999, Dr. Carroll became part of the CNS Pharmacology Department at Pfizer. While at Pfizer (currently the largest pharmaceutical company in the world), he performed significant roles in drug discovery research and co-chaired drug discovery projects.
In 2005, Dr. Carroll left industry to pursue his interests in basic research and teaching. He initially joined the Department of Chemistry at the University of Toledo for two years, prior to joining the Northeastern Ohio Universities College of Pharmacy.
In addition to Dr. Carroll's extensive work in CNS drug discovery, he has co-authored over 35 articles in peer-reviewed journals and book chapters, presented numerous papers at national and international scientific meetings, and contributed to two patents. His support of the scientific community includes his contributions as a Review Editor of “Frontiers in Alzheimer’s disease” and reviewer of grants and scientific articles for several organizations and journals respectively. Dr. Carroll's research interests focus on the development of novel drugs aimed at abnormal mitochondrial function found in neurodegenerative and neurodevelopmental diseases. He is a member of several scientific organizations including the Society for Neuroscience and the American Chemical Society.
1993: Ph.D. in Chemistry, Department of Chemistry, University of Toledo, Toledo, OH
1991: M.S. in Chemistry, Department of Chemistry, University of Toledo, Toledo, OH
1988: B.S. in Biology, Department of Biology, University of Toledo, Toledo, OH
2008-present: Graduate Faculty Member (Neuroscience and Pharmacology), Kent State University, School Biomedical Sciences, Kent, OH
2007-present: Associate Professor, Department of Pharmaceutical Sciences, Northeastern Ohio Universities College of Pharmacy, Rootstown, OH
2005-2007: Instructor, Visiting Assistant Professor and Research Assistant Professor, Department of Chemistry, University of Toledo, Toledo, OH
1999-2005: Senior Principal Scientist, Pfizer Inc, CNS Pharmacology, Ann Arbor, MI
1991-1999: Senior Scientist, Parke-Davis, Neuroscience Therapeutics
To therapeutically target novel mechanisms involved in aberrant mitochondrial function leading to neurodevelopmental and neurodegenerative diseases including autism, Alzheimer’s disease and Parkinson’s disease. This research focuses on mitochondrial proteins that regulate bioenergetics, mitochondrial dysfunction, translational neuropharmacology, and drug discovery. Dysfunctional mitochondrial work being performed; has also been shown to be applicable to cancer, stroke and cardiovascular disease.
Geldenhuys WJ, Funk MO, Awale PS, Lin L, Carroll RT. A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5498-501.
Carroll RT, Dluzen DE, Stinnett H, Awale PS, Funk MO, Geldenhuys WJ. Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4798-803.
Arif W, Xu S, Isailovic D, Geldenhuys WJ, Carroll RT, Funk MO. Complexes of the outer mitochondrial membrane protein mitoNEET with resveratrol-3-sulfate. Biochemistry. 2011 Jun 28;50(25):5806-11.
Geldenhuys, W.J., Youdim, M.B.H., Carroll, R.T., and Van der Schyf, C.J. The Emergence of Designed Multiple Ligands for Neurodegenerative Disorders. Progress in Neurobiology, 2011, 94, 347-359.
Mbimba, T., Awale, P., Bhatia, D., Geldenhuys, W.J., Darvesh, A.S., Carroll, R.T., Bishayee, A. Alteration of Hepatic Proinflammatory Cytokines is Involved in the Resveratrol-Mediated Chemoprevention of Chemically-Induced Hepatocarcinogenesis. Curr Pharm Biotechnol. -- in press (2011).
Geldenhuys, W.J., Bishayee, A., Darvesh, A.S., Carroll, R.T. Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design. Curr Pharm Biotechnol. -- in press (2011).
Geldenhuys WJ, Funk MO, Awale PS, Lin L, Carroll RT. “A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET.” Bioorg Med Chem Lett. 2011 Sep 15;21(18):5498-501.
Carroll RT, Dluzen DE, Stinnett H, Awale PS, Funk MO, Geldenhuys WJ. “Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.” Bioorg Med Chem Lett. 2011 Aug 15;21(16):4798-803.
Arif W, Xu S, Isailovic D, Geldenhuys WJ, Carroll RT, Funk MO. “Complexes of the outer mitochondrial membrane protein mitoNEET with resveratrol-3-sulfate.” Biochemistry. 2011 Jun 28;50(25):5806-11.
Darvesh, A.S., Carroll, R.T., Geldenhuys, W.J., Gudelsky, G.A., Klein, J., Meshul, C.K., and Van der Schyf, C.J. In vivo brain microdialysis: advances in neuropsychopharmacoloy and drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 109-127.
Geldenhuys, W.J., Darvesh, A.S., Funk, M.O., Van der Schyf, C.J., Carroll, R.T. Identification of Novel Monoamine Oxidase-B Inhibitors by Structure-Based Virtual Screening. Bioorg Med Chem Lett. 2010 Sep 1:20(17):5295-8.
Geldenhuys, W.J., Funk, M.O., Barnes, K.F., Carroll, R.T. Structure-Based Design of a Thiazolidinedione Which Targets the Mitochondrial Protein mitoNEET. Bioorg. Med. Chem. Lett., 20, 819 (2010).
Carroll, R.T., Bhatia, D., Geldenhuys, W.J., Sutariya, V.B. Brain targeted delivery of Tempol nanoparticles for neurological disorders. J of Drug Target. 2010 Nov;18(9):665-74.
Bishayee, A., Barnes, K.F., Darvesh, A.S., Carroll, R.T. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res., 3, 753 (2010).
Darvesh, A.S., Carroll, R.T., Bishayee, A., Geldenhuys, W.J., Van der Schyf, C.J. Oxidative stress and Alzheimer’s disease: dietary polyphenols as therapeutic agents. Expert Rev Neurother. 10, 729 (2010).
Hu, L.Y., Boxer, P.A., Kesten, S.R., Lei, H.J., Wustrow, D.J., Moreland, D.W., Zhang, L., Ahn, K., Ryder, T.R., Liu, X., Rubin, J.R., Fahnoe, K., Carroll, R.T., Dutta, S., Fahnoe, D.C., Probert, A.W., Roof, R.L., Rafferty, M.F., Kostlan, C.R., Scholten, J.D., Hood, M., Ren, X.D., Schielke, G.P., Su, T.Z., Taylor, C.P., Mistry, A., McConnell, P., Hasemann, C., Ohren, J. The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases. Bioorganic & Medicinal Chemistry Letters. 2337-2340, vol 16, 2006.
Skrzypczak-Jankun, E., Bross, R., Carroll, R.T., Dunham, W.R. and Funk, M.O. Purple Lipoxygenase is an Iron-Peroxide Complex. J. Am. Chem. Soc. 10814-20, vol 123, 2001.
Althaus, J.S., Schmidt, K.R., Fountain, S.T., Tseng, M.T., Carroll, R.T., Galatsis, P., Hall, E.D. LC-MS/MS Detection of Peroxynitrite-Derived 3-Nitrotyrosine in Rat Microvessels. Free Radic. Biol. Med. 1085-95, vol. 11, 2000.
Carroll, R.T., Galatsis, P., Kopec, K.K., V. Kumar, Borosky, Althaus, S.J. and Hall, E.D. 4-Hydroxy-2,2,6,6-Tetramethyl-Piperidine-1-Oxyl (Tempol) Acts as a Catalytic Scavenger of Peroxynitrite. Chemical Research in Toxicology, 294-300, vol. 13, 2000.
Walker, L.C., Parker, C.A., Lipinski, W.J., Callahan, M.J., Carroll, R.T., Gandy, S.E., J.D. Smith, M., Jucker, C.L., Bisgaier. Cerebral Lipid Deposition in Aged ApoE-Deficient Mice. Am. J. Pathology 1371-1377, vol. 151, 1997.
Mazur-Kolecka, B., Frackowiak, J., Carroll, R.T. and Wisniewski, H.M. Accumulation of Alzheimer Amyloid-b Peptide in Cultured Myocytes is Enhanced by Serum and Reduced by Cerebrospinal Fluid. J Neurophathol Exp. Neurol, 263-273, vol. 56, 1997.
Emmerling, M.R., Dudley, D.T., Dyer, R.D., Carroll, R.T., Doyle, P.D. and Davis, R.E. The Role of Arachidonic Acid in the Secretion of the Amyloid Precursor Protein. The Neurobiology of Alzheimer’s Disease, 310-315, vol. 777, 1996.
Vasilakos, J.P., Ghayur, T., Carroll, R.T., Giegel, D.A., Saunders, J.M., Quintal, L., Keane, K.M. and Shivers, B.D. J. Interleukin-1ß Converting Enzyme (ICE) is not Required for Apoptosis Induced by Lymphokine Deprivation in an IL-2-Dependent T-Cell Line. Immunology, 3433-42, vol. 155, 1995.
Emmerling, M.R., Grassi, J. and Carroll, R.T. Acetylcholinesterase is not a Protease. Alzheimer’s and Parkinson’s diseases: Recent Developments 259-266, vol. 44, 1995.
Emmerling, M.R., Moore, C.J., Doyle, P.D., Carroll, R.T. and Davis, R.E. Cell Surface Receptor Mediated Control of Amyloid Precursor Protein Secretion: Involvement of Pleiotropic Signal Transduction Cascades. Alzheimer’s and Parkinson’s diseases: Recent Developments 131-139, vol. 44, 1995.
Carroll, R.T., Grimm, J.L., Hepburn, T.W. and Emmerling, M.R. Purification of Acetylcholinesterase by Tacrine Affinity Chromatography. Protein Expression and Purification 389-393, vol. 6, 1995.
Frackowiak, J., Mazur-Kolecka,B., Wisniewski, H.M., Potempska, A., Carroll, R.T., Emmerling, M.R. and Kim, K.S. Secretion and Accumulation of ß-protein by Cultured Vascular Smooth Muscle Cells From Old and Young Dogs. Brain Research 225-230, vol 676, 1995.
Vasilakos, J.P., Carroll, R.T., Emmerling, M.R., Doyle, P.D., Davis, R.E., Kim, K.S., and Shivers, B.D. Interleukin-1ß Dissociates ß-amyloid Precursor Protein and ß-amyloid Peptide Secretion. FEBS Lett. 289-292, vol. 354, 1994.
Emmerling, M.R., Doyle, P.D., Moore, C.J., Carroll, R.T., and R.E. Davis. Phospholipase A2 Activation Influences the Processing and Secretion of the Amyloid Precursor Protein. Bioch. Biophys. Res. Comm. 292-297, vol. 197, 1993.
Carroll, R.T., Grimm, J. L., Dunham, W.R. and Funk, M.O. Rapid Purification of Rabbit Reticulocyte Lipoxygenase for Electron Paramagnetic Spectroscopy Characterization of the Non-Heme Iron. Lipids, 241-244, vol. 28, 1993.
Nassereddine-Sebaei, M., Crider, A.M., Carroll, R.T. and C.N. Hinko. Determination of M-Nitrophenol and Nipecotic Acid in Mouse Tissues by High-Performance Liquid Chromatography after Administration of the Anticonvulsant m-Nitrophenyl-3-piperidinecarboxylate Hydrochloride. Journal of Pharmaceutical Sciences 39-43, vol. 82, 1993.
Ramachandran, S., Carroll, R.T., Dunham, W.R. and Funk, M.O. Limited Proteolysis and Active-Site Labeling Studies of Soybean Lipoxygenase 1. Biochemistry 7700-7706, vol. 31, 1992.
Carroll, R.T. and Emmerling, M.R. Identification of the Trypsin-like Activity in Commercial Preparations of Eel Acetylcholinesterase. Biochem. Biophys. Res. Comm. 858-862, vol. 181, 1991.
Richard T. Carroll Jr.; Lamia Sharmeen. Therapeutic combination for attention deficit hyperactivity disorders. (2005), WO-2005115396.
Richard T. Carroll, Richard Dyer, Lillian Robichaud and Brenda Shivers. Methods For Treating and Preventing Neurodegenerative Disorders. (1999) WO-09802160.
Funk, M.O., Carroll, R.T., Finnen, D.C., Pinkerton, A.A. and Dunham, W.R. The Role of Iron in Lipoxygenase Catalysis. Selective Reactions of Metal-Activated Molecules, H. Werner, A.G. Griesbeck, W. Adam, G. Bringmann, and W. Kiefer (Eds.): Braunschweig, 51-61, 1992.
Davis, R.E., Doyle, P.D., Carroll, R.T. and Emmerling, M.R. Cholinergic Therapies for Alzheimer’s Disease: Palliative or Disease Altering? Arzneimittel - Forschung/Drug Research 425-431, vol. 45, 1995.